Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Roivant Sciences Ltd shares valued at $14,937,500 were sold by Ramaswamy Vivek on Sep 03 ’25. At $12.50 per share, Ramaswamy Vivek sold 1,195,000 shares. The insider’s holdings dropped to 36,089,108 shares worth approximately $551.44 million following the completion of this transaction.
Also, Ramaswamy Vivek sold 385,816 shares, netting a total of over 5,000,175 in proceeds. Following the sale of shares at $12.96 each, the insider now holds 35,508,359 shares.
Before that, Ramaswamy Vivek had sold 194,933 shares from its account. In a trade valued at $2,518,534, the 10% Owner traded Roivant Sciences Ltd shares for $12.92 each. Upon closing the transaction, the insider’s holdings decreased to 194,933 shares, worth approximately $548.46 million.
As published in their initiating research note from Citigroup on September 02, 2025, Roivant Sciences Ltd [ROIV] has been a Buy and the price target has been revised to $16. As of February 15, 2024, Wolfe Research has initiated its “an Outperform” rating for ROIV. Earlier on January 05, 2024, Piper Sandler initiated its rating. Their recommendation was “an Overweight” for ROIV stock.
Analyzing ROIV Stock Performance
On last trading session, Roivant Sciences Ltd [NASDAQ: ROIV] rose 7.76% to $15.28. The stock’s lowest price that day was $15.22, but it reached a high of $16.05 in the same session. During the last five days, there has been a surge of approximately 10.97%. Over the course of the year, Roivant Sciences Ltd shares have jumped approximately 27.97%.
Is Roivant Sciences Ltd subject to short interest?
Stocks of Roivant Sciences Ltd saw a sharp rise in short interest on 2025-08-29 jumping by 0.74 million shares to 39.05 million. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 38.31 million shares. A jump of 1.89% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 8.74 of the overall float, the days-to-cover ratio (short ratio) jumped to 8.74.
Which companies own the most shares of Roivant Sciences Ltd (ROIV)?
In terms of Roivant Sciences Ltd share price expectations, FactSet research, analysts set an average price target of 17 in the next 12 months, up nearly 19.89% from the previous closing price of $14.18. Analysts anticipate Roivant Sciences Ltd stock to reach 20 by 2025, with the lowest price target being 12.5. In spite of this, 7 analysts ranked Roivant Sciences Ltd stock as Buy at the end of 2025. On December 12, 2023, Deutsche Bank assigned a price target of “a Buy” to the stock and initiated coverage with a $14.
